Article Text

PDF
Short report
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
  1. Antoine Gueguen1,
  2. Pascal Roux2,
  3. Romain Deschamps1,
  4. Antoine Moulignier1,
  5. Caroline Bensa1,
  6. Julien Savatovsky2,
  7. Françoise Heran2,
  8. Olivier Gout1
  1. 1Department of Neurology, Fondation Ophtalmologique A. de Rothschild, Paris, France
  2. 2Department of Medical Imaging, Fondation Ophtalmologique A. de Rothschild, Paris, France
  1. Correspondence to Dr Antoine Guéguen, Department of Neurology, Fondation Ophtalmologique A. de Rothschild, 25–29, rue Manin, Paris 75019, France; agueguen{at}fo-rothschild.fr

Abstract

Objective To characterise recurrence of multiple sclerosis (MS) inflammatory activity during the year following natalizumab (NTZ) cessation.

Methods Thirty-two patients with MS were included in a monocentric cohort study. Data were collected prospectively during and after NTZ, with serial clinical and MRI evaluations. The first relapse occurring after interrupting NTZ was the primary outcome measure. The numbers of gadolinium-enhancing lesions before, during and after NTZ treatment, were compared.

Results During the year following NTZ cessation, the cumulative probability of relapses was estimated at 52.9% and an unusually high MRI inflammation was noticed. It was defined by a number of gadolinium-enhancing lesions >5 and exceeding the gadolinium lesions existing before NTZ initiation. Rebound of MS activity after NTZ cessation was characterised by association of relapses and unusual MRI inflammation. Cumulative probability of rebound was estimated at 39% and mostly occurring between 3 months and 9 months after interrupting NTZ. Risk of rebound appears related with a higher annualised relapse rate and a lower Expanded Disability Status Scale score before NTZ initiation. Rebound was associated with severe recurring relapses in 9% of the patients.

Conclusions This study identifies rebound after NTZ cessation as an association of relapses and high MRI activity.

  • Multiple Sclerosis
  • MRI

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.